Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors.
Serum levels of fucosyltransferase (FT), phosphohexoseisomerase (PHI), tissue polypeptide antigen (TPA), Tennessee antigen (TAG), carcinoembryonic antigen (CEA) and prostatic acid phosphate (PAP) were determined in 75 healthy individuals and in 86 patients with prostatic carcinoma and 38 patients with bladder tumors. The discrimination capacities of the different markers were compared by using inverse distribution plots. At a rate of 5% false positive values the sensitivities for bladder tumors were: FT 30%, TPA 24%, CEA 16%, TAG 15%. The sensitivities for prostatic carcinoma were: PAP 63%, PHI 36%, TPA 18%, CEA 14%, TAG 14%.
D000135:Acid Phosphatase / Q000097:blood; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D005647:Fucosyltransferases / Q000097:blood; D005956:Glucose-6-Phosphate Isomerase / Q000097:blood; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood*; D019396:Tissue Polypeptide Antigen; D001749:Urinary Bladder Neoplasms / Q000097:blood*
D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D007527:Isoenzymes; D010455:Peptides; C033814:Tennessee antigen, human; D019396:Tissue Polypeptide Antigen; D005647:Fucosyltransferases; D000135:Acid Phosphatase; D005956:Glucose-6-Phosphate Isomerase